TY - JOUR
T1 - Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer
AU - Carneiro, Benedito A.
AU - Ramanathan, Ramesh K.
AU - Fakih, Marwan G.
AU - Krishnamurthi, Smitha S.
AU - Lembersky, Barry C.
AU - Stoller, Ronald G.
AU - Lancaster, Stewart L.
AU - Pinkerton, Richard A.
AU - Crandall, Theodore L.
AU - Schmotzer, Amy R.
AU - Potter, Douglas M.
AU - Bahary, Nathan
PY - 2012/3/1
Y1 - 2012/3/1
N2 - Irinotecan and weekly cetuximab (I+C) is a standard second-line regimen for metastatic colorectal cancer (mCRC). This phase II study investigated the efficacy of every 2 weeks (q2wks) I+C in 31 patients with mCRC. The RR (primary outcome) and time to progression were lower than expected possibly reflecting the reduced dose intensity due to toxicities. TheOSwas consistent with previous publications, however the efficacy of q2wksC+I was not demonstrated. Background: Irinotecan and weekly cetuximab (I+C) is a standard second-line regimen for metastatic colorectal cancer (mCRC). This study investigated the safety and efficacy of every 2 weeks I+C in patients with mCRC. Patients and Methods: Patients with mCRC refractory to first-line fluoropyrimidine/oxaliplatin regimens and not previously treated with I+C were eligible. Response rate (RR) was the primary endpoint. Cetuximab 500 mg/m2 and irinotecan 180 mg/m2 were administered intravenously (I.V.) on day 1 every 2 weeks. Results: Patient characteristics (n = 31): male (n = 17), median age 62; Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1 (n = 30), and PS = 2 (n = 1). Median number of cycles = 3 (range, 1-22). I+C doses were modified in 18 and 12 patients, respectively. Grade 3/4 ad verseevents: acneiform rash (n=6); neutropenia (n=6); and diarrhea (n=5); there was one grade 5 respiratory failure, possibly related to therapy. Two patients had a partial response, 11 had stable disease, and 18 had progressive disease resulting in an overall RR of 6% and disease control rate of 41.9%. Median overall survival (OS) was 9.3 months (95% CI, 5.1-15), and time to progression (TTP) was 2.4 months (95% CI, 1.3-4.6). K-ras and BRAF mutations were detected in 39% and 9%, respectively, of the patients tested. There was a trend toward longer TTP among patients with wild-type K-ras and BRAF (2.6 vs. 1.7 months; P = 0.16), and OS was significantly longer in those patients (14.1 vs. 5.5 months; P = 0.04). Conclusions: The RR and TTP were lower than expected and may reflect the reduced dose intensity due to toxicities. While the OS was consistent with previous publications, the efficacy of this combination was not demonstrated.
AB - Irinotecan and weekly cetuximab (I+C) is a standard second-line regimen for metastatic colorectal cancer (mCRC). This phase II study investigated the efficacy of every 2 weeks (q2wks) I+C in 31 patients with mCRC. The RR (primary outcome) and time to progression were lower than expected possibly reflecting the reduced dose intensity due to toxicities. TheOSwas consistent with previous publications, however the efficacy of q2wksC+I was not demonstrated. Background: Irinotecan and weekly cetuximab (I+C) is a standard second-line regimen for metastatic colorectal cancer (mCRC). This study investigated the safety and efficacy of every 2 weeks I+C in patients with mCRC. Patients and Methods: Patients with mCRC refractory to first-line fluoropyrimidine/oxaliplatin regimens and not previously treated with I+C were eligible. Response rate (RR) was the primary endpoint. Cetuximab 500 mg/m2 and irinotecan 180 mg/m2 were administered intravenously (I.V.) on day 1 every 2 weeks. Results: Patient characteristics (n = 31): male (n = 17), median age 62; Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1 (n = 30), and PS = 2 (n = 1). Median number of cycles = 3 (range, 1-22). I+C doses were modified in 18 and 12 patients, respectively. Grade 3/4 ad verseevents: acneiform rash (n=6); neutropenia (n=6); and diarrhea (n=5); there was one grade 5 respiratory failure, possibly related to therapy. Two patients had a partial response, 11 had stable disease, and 18 had progressive disease resulting in an overall RR of 6% and disease control rate of 41.9%. Median overall survival (OS) was 9.3 months (95% CI, 5.1-15), and time to progression (TTP) was 2.4 months (95% CI, 1.3-4.6). K-ras and BRAF mutations were detected in 39% and 9%, respectively, of the patients tested. There was a trend toward longer TTP among patients with wild-type K-ras and BRAF (2.6 vs. 1.7 months; P = 0.16), and OS was significantly longer in those patients (14.1 vs. 5.5 months; P = 0.04). Conclusions: The RR and TTP were lower than expected and may reflect the reduced dose intensity due to toxicities. While the OS was consistent with previous publications, the efficacy of this combination was not demonstrated.
KW - Biweekly
KW - Cetuximab
KW - EGFR
KW - Irinotecan
UR - http://www.scopus.com/inward/record.url?scp=84856449721&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856449721&partnerID=8YFLogxK
U2 - 10.1016/j.clcc.2011.05.003
DO - 10.1016/j.clcc.2011.05.003
M3 - Article
C2 - 21813336
AN - SCOPUS:84856449721
SN - 1533-0028
VL - 11
SP - 53
EP - 59
JO - Clinical colorectal cancer
JF - Clinical colorectal cancer
IS - 1
ER -
